Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

BACKGROUND: Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because they release large amounts of various mediators that sustain the inflammatory network. Masitinib, a sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermersch, Patrick, Benrabah, Rabah, Schmidt, Nicolas, Zéphir, Hélène, Clavelou, Pierre, Vongsouthi, Cyrille, Dubreuil, Patrice, Moussy, Alain, Hermine, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467179/
https://www.ncbi.nlm.nih.gov/pubmed/22691628
http://dx.doi.org/10.1186/1471-2377-12-36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467179/
https://www.ncbi.nlm.nih.gov/pubmed/22691628
http://dx.doi.org/10.1186/1471-2377-12-36

Ejemplares similares